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Abstract: Background: We analyzed the immediate effects of a Telerehabilitation Program (TP)
based on aerobic exercise in women with fibromyalgia (FM) syndrome during the lockdown declared
in Spain due to the COVID-19 pandemic. Methods: A single-blind randomized controlled trial was
designed. Thirty-four women with FM were randomized into two groups: TP group and Control
group. The intervention lasted 15 weeks, with 2 sessions per week. The TP based on aerobic exercise
was guided by video and the intensity of each session was monitored using the Borg scale. Pain in-
tensity (Visual Analogue Scale), mechanical pain sensitivity (algometer), number of tender points,
FM impact (Revised Fibromyalgia Impact Questionnaire), pain catastrophizing (Pain Catastrophiz-
ing Scale), physiological distress (Hospital Anxiety and Depression Scale), upper (Arm Curl Test)
and lower-limb physical function (6-min Walk Test) were measured at baseline and after the interven-
tion. Results: The TP group improved pain intensity (p = 0.022), mechanical pain sensitivity (p < 0.05),
and psychological distress (p = 0.005), compared to the Control group. The Control group showed no
statistically significant changes in any variable (p > 0.05). Conclusions: A TP based on aerobic exercise
achieved improvements on pain intensity, mechanical pain sensitivity, and psychological distress
compared to a Control group during the lockdown declared in Spain due to COVID-19 pandemic.
Keywords: fibromyalgia; chronic pain; exercise; rehabilitation; telerehabilitation
1. Introduction
Fibromyalgia (FM) is a chronic disorder characterized by persistent widespread pain
and commonly associated with psychological distress, pain catastrophizing and lower
levels of physical function among other symptoms [1–3]. The FM worldwide prevalence
has been estimated in 2.1% and has shown to be higher among women, at a rate of 4:1 [4].
The World Health Organization declared in March 2020 the COVID-19 as a global
pandemic [5]. Most countries carried out measures such as lockdown and restrictions to
prevent the spread of COVID-19 and reduce the infection risk. These restrictions have
resulted in negative effects by limiting the participation in normal daily living, social
and physical activities, and the access to many forms of exercise [6,7]. The direct and
indirect consequences derived from the pandemic situation have affected the health status
of patients with chronic diseases [8]. Patients with FM have reported an increase in pain
intensity, pain catastrophizing, physiological distress, and sedentary lifestyles affecting
negatively to the quality of life and social aspect of these patients [3,9–11].
Clinical guidelines recommend the use of conservative non-pharmacological therapies
as a first-line intervention for patients with FM [12,13]. The aerobic exercise is one of the
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most accepted modalities. Recent studies showed that individualized low-intensity aerobic
exercise was well-tolerated by patients with FM [14–16]. These studies achieved positive
effects on pain intensity, FM impact, hyperalgesia, physical function, catastrophizing,
and psychological distress [14–16], without major adverse events [14]. In addition, aerobic
exercise showed lower costs and larger positive effects compared to usual care [17].
Given the high professional and economic requirements in the health care system
during the COVID-19 pandemic, the design of therapeutic strategies without the risk
of viral infection has become necessary, and telerehabilitation has been proposed as a
feasible method [18]. Telerehabilitation has been developed in the last years and implies
the substitution of traditional face-to-face approaches by telematic procedures, using tele-
phone, video, and computer technologies [19]. Telerehabilitation allows guide some
therapies to maintain social distance, while keeping the therapist–patient communication
and monitoring [20–22].
Our hypothesis is that a telerehabilitation program (TP) based on aerobic exercise
could improve the main FM symptoms in patients with FM.
Therefore, the purpose of this study was to analyze the immediate effects on pain
intensity, mechanical pain sensitivity, FM impact, pain catastrophizing, psychological
distress, and physical function of a TP based on aerobic exercise in patients with FM during
the period of mobility restrictions imposed by the COVID-19 pandemic.
2. Material and Methods
2.1. Study Design
We conducted a single-blind randomized controlled trial to analyze the effects of a TP
based on aerobic exercise in patients with FM. This study was carried out at the Faculty of
Health Sciences of the University of Valladolid from March to June 2020 (lockdown period
in Spain) and was developed according to CONSORT guidelines. The ethical approval was
obtained from the Research Ethics Committee of Valladolid Este (19-410) and the study
was registered at clinicaltrials.gov (NCT04340674).
2.2. Participants
The participants were referred by a rheumatologist from February to March 2020.
Thirty-seven patients diagnosed with FM (mean years since diagnosis ± SD: 10.54 ± 7.4)
were screened of which 37 women aged from 30 to 75 (mean ± SD: 53.44 ± 8.8) years,
participated in the study.
The inclusion criteria were: women diagnosed with FM by a rheumatologist according
to the latest diagnostic criteria of the American College of Rheumatology [23], aged from
30 to 75 years, and having access to internet with any type of digital device.
The exclusion criteria were: presence of other systemic, somatic, or psychiatric dis-
eases, pregnancy or lactation, previous physiotherapy treatments, or modifications in
pharmacological treatments during the study or in the last 3 months before the interven-
tion, exercise contraindications, or inability to communicate with examiners.
2.3. Sample Size
The calculation of the sample size was performed based on the primary dependent
variable (pain intensity). Seventeen patients per group were estimated assuming a standard
deviation of 1.9 previously reported in a pilot study in patients with FM and a between-
group mean difference of 2 cm in the Visual Analogue Scale (VAS), which is considered
as the minimum relevant change, establishing an α error of 5%, a β error of 20%, and a
follow-up loss rate of 15%. The software used for the sample size calculation was Minitab®
program version 13.0.
2.4. Randomization
All the participants that met the inclusion and exclusion criteria were randomly
allocated to the TP group or to the Control group. The allocation (ratio 1:1) was performed
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by an independent researcher who did not participate in the data acquisition or statistical
analysis, using the GraphPad computer software 2018 (GraphPad Software, San Diego,
CA, USA) [24].
2.5. Interventions
The TP group received 15 weeks of a telerehabilitation aerobic exercise program.
The Control group received no additional interventions. Both the TP group and the Control
group were asked to maintain the same medical prescription during the study.
The intervention was performed by an experienced physiotherapist with more than
4 years of clinical experience in therapeutic exercise for chronic diseases, who was blinded
to the measurements.
The TP group completed 30 sessions of exercise, during 15 weeks, with 2 sessions per
week [20,25]. Telerehabilitation sessions were based on low-impact rhythmic movements,
guided by video, according to the protocol of Schachter et al. [26]. The TP was designed
according to American Pain Society guidelines on FM, that recommended moderately
intense aerobic exercise 2–3 times per week [27] and included 3 parts: warm-up, central
part, and cool-down. Each session lasted 50 min.
The warm-up consisted of joint mobility exercises and active stretching. In the central
part, the aerobic exercises were based on low-impact rhythmic movements guided by video.
The repetition rate determines the intensity of the exercises: 10, 15, 20, or 25 repetitions per
minute. The patients could watch the four intensities of each exercise performed by the
therapist on video. The first two sessions were supervised before telerehabilitation sessions
to ensure that the patients performed the exercises in a correct and safe way and allowed to
establish the intensity of the protocol at the beginning of the intervention. The exercise intensity
of each telerehabilitation session was individually adjusted by the participants’ Modified Borg
perceived exertion reported in previous session. The Modified Borg Scale ranges from 0 to 10
points with higher scores representing higher physical exertion [28] and has shown to be a valid
tool to determine intensity in FM patients [29]. The exercise intensity was increased if the Borg
rate was less than 4 and intensity was decreased if the Borg rate was more than 7, according
to the protocol described by Duruturk et al. [30]. The cool-down part was based on statis
stretching of the major muscles (3 sets of 30 s) and breathing techniques. The physiotherapist,
who performed the intervention, adapted and controlled all the exercises to avoid any adverse
event and to ensure patients’ safety.
Participants of both groups were called by video call, once a week. The participants of
the TP group were called to control and individualize the exercises. The participants of the
Control group were contacted to ensure that they maintained the same conditions during
the study.
The treatment adherence was registered using an online attendance record Google
Forms software (Google LLC, Menlo Park, CA, USA).
2.6. Outcome Measures
The measurements were performed the previous week before the lockdown, by two
physiotherapists blinded to the group assignment. Clinical and demographic information
including age, sex, height, weight, body mass index, and medication intake were recorded
at baseline. All the outcome measures were assessed at baseline and after the intervention.
Primary outcome
The main outcome measure was pain intensity. Pain intensity was registered using
the 10-cm VAS, in which 0 represented “no pain” and 10 represented “the most intense
pain imaginable.” This scale showed excellent reliability in chronic pain subjects, with an
Intraclass Correlation Coefficient (ICC) of 0.97–0.99 [31,32].
Secondary outcomes
Mechanical pain sensitivity was evaluated with an analogical pressure algometer
(Psymtec, FPK 20, Wagner Instruments, Greenwich, USA). The 18 tender points described
in the 1990 ACR criteria were assessed [33]. The tender points were right and left occiput,
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low cervical, trapezius, supraspinatus, second rib, lateral epicondyle, gluteal, greater
trochanter, and knee. The mechanical pain sensitivity threshold was measured with the
algometer applying increasing pressure on each tender point where the sense of pressure
change to pain was registered as the pain threshold. Pressure was increased at a rate
of 1 kg/s. Participants were instructed to say “stop” when the pressure became to clear
sensation of pain. The number of tender points and the algometer score were analyzed after
the measurements. A tender point was considered if the threshold was ≤ 4 kg/cm2 [33].
The algometer score was calculated as the sum of the pain-pressure values obtained for
each tender point. Mechanical pain sensitivity measured through algometry has shown
good to excellent reliability in different body regions (ICC = 0.82–0.97) [34,35].
FM impact was measured using the Spanish version of the Revised Fibromyalgia
Impact Questionnaire (FIQ-R). This questionnaire consists of 21 questions based on an
11-point numeric rating scale of 0 to 10. The scores range from 0 to 100, with higher
scores representing higher FM impact. The reliability of the questionnaire has shown to be
excellent (ICC = 0.81) [36].
The Spanish version of the Pain Catastrophizing Scale (PCS) was used to measure
catastrophizing cognitions related to pain. This scale assesses the dimensions of rumination,
magnification, and helplessness and consists of 14 items, with each item rated from 0 (not at
all) to 4 (all the time). The total score ranged from 0 to 52 points, and higher values show
higher pain catastrophizing. Total score and dimensions were registered. The Spanish
version of PCS has shown good test–retest reliability in FM patients (ICC = 0.84) [37].
Psychological distress was measured using the Hospital Anxiety and Depression
Scale (HADS). The scale includes an anxiety subscale (HADS-A) and a depression subscale
(HADS-D), with 7 items into each subscale. Subscale scores range from 0 to 21, with higher
scores representing higher anxiety or depression levels. Total score and subscales were
registered. The HADS has shown good test–retest reliability (ICC = 0.84–0.94) [38,39].
The upper and lower limbs’ physical function was measured with the 6-min Walk
Test (6MWT) and with the Arm Curl Test (ACT), respectively. The 6MWT measures the
maximum distance in meters that an individual is able to walk, as fast as possible, during
the period of 6 min. In the ACT test, the patients, seated on a chair with backrest and
holding a dumbbell (2.3 kg) with the elbow extended, had to flex and extend the elbow
as many times as possible in 30 s [40]. Both tests have shown excellent reliability in FM
patients (6MWT ICC: 0.91–0.98; ACT ICC: 0.81–0.86) [41,42].
2.7. Statistical Analysis
An assessor blinded to the treatment allocation conducted the statistical analysis using
SPSS software, version 24.0. The statistical analysis was conducted according to intention-
to-treat (ITT). Mean and standard deviations were calculated for quantitative variables.
Frequencies and percentages were calculated for qualitative variables. The Shapiro-Wilk
test was used to assess the normal distribution of quantitative variables. Between-group
comparisons of clinical and demographic variables were analyzed using the Student´s t-test
for normally distributed data or the Mann–Whitney U test for non-normally distributed
data. Chi-square test (X2) was used for between-group comparison of nominal variables.
A two-way ANOVA was used to analyze the differences in outcomes with time
(baseline and postintervention) as the within-subjects factor and group (TP group and
Control group). A p-value < 0.05 was considered statistically significant. The effect size
(Cohen’s d) was also calculated, to estimate the magnitude of the differences within and
between groups. The magnitude of difference was classified as small if the value of Cohen’s
d ranged from 0.2 to 0.5, as moderate if it ranged from 0.5 to 0.8 or, as large if Cohen’s
d value was greater than 0.8.
3. Results
Thirty-seven patients diagnosed with FM were screened. Three patients were ex-
cluded: 2 patients did not meet the inclusion criteria and 1 patient declined to participate
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for personal reasons. Thirty-four female patients that met the eligibility criteria signed
the informed consent and were randomized into the TP group (n = 17) or the Control
group (n = 17). Six patients failed to complete the study: three patients in the TP group
and three patients in the Control group. The flowchart diagram of the recruitment and
follow-up of participants is shown in Figure 1. Demographic and medication intake at
baseline are shown in Table 1. No statistically significant differences were found between
both groups at baseline (p > 0.05). Adherence to the TP group over the 10 weeks was high,
averaging 89.9%.
After the intervention, a two-way ANOVA showed significant Group by Time interac-
tions for pain intensity (F = 5.99; p = 0.021), mechanical pain sensitivity (Algometer score:
F = 10.67; p = 0.003; active points: F = 7.90; p = 0.009), and psychological distress (F = 12.03;
p = 0.002). The TP group showed a greater decrease in pain intensity (∆1.53 (0.04 to 3.03)
and in psychological distress (∆9.54 (3.09 to 15.99) and a greater increase in mechanical
pain sensitivity (algometer score: ∆−14.06 (−26.20 to −1.92); tender points: ∆2.65 (0.18 to
5.11) than the Control group. The results achieved for these variables in the PT group
showed a large effect size (>0.8). There were no statistically significant differences between
both groups on FM impact, pain catastrophizing, and physical function (p > 0.05).
Regarding within-group change scores, the PT group showed a statistically significant
improvement in all the variables (p < 0.05) except in the rumination PCS subscale (p = 0.078)
and in the 6MWT (p = 0.051). No within-groups differences were found in any variable in
the Control group (p > 0.05). Table 2 provides before and after intervention data, within-
and between-groups differences as well as the effect size for all the dependent variables.
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Table 1. Baseline characteristics of the study population.
TP Group
Mean ( ± SD)
Control Group
Mean ( ± SD) Significance
Age (years) 51.81 ± 9.05 55.06 ± 8.51 0.304 a
Height (cm) 158.63 ± 6.29 161.81 ± 5.13 0.191 b
Weight (kg) 68.19 ± 16.88 68.13 ± 15.10 0.836 b
BMI (kg/cm2) 27.25 ± 7.30 25.93 ± 5.27 0.598 b
Medication n (%) 17 (100) 17 (100) 0.224 c
Anxiolytics n (%) 9 (53) 7 (41)
Antidepressants n (%) 9 (53) 9 (53)
Anti-inflammatory n (%) 14 (82) 8 (47)
Analgesic n (%) 11 (65) 12 (71)
Muscle relaxant n (%) 4 (24) 2 (12)
a: Student´s t-test; b: Mann–Whitney U; c: Chi-square. Values for quantitative data are expressed in mean and standard deviation,
and values for medication are expressed as percentages (%) and frequencies (n).
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Table 2. Primary and secondary outcomes at baseline and after intervention as well as within-group mean scores.
Baseline
Mean ± SD (95% CI)
Postintervention











TP group 7.08 ± 1.45 (6.38 to 7.78) 4.92 ± 2.00 (3.85 to 6.00) 2.15 (1.37, 2.94) <0.001 −1.2 F = 5.990.021 0.8
Control group 7.29 ± 1.07 (6.62 to 7.96) 6.46 ± 1.92 (5.42 to 7.50) 0.82 (−0.3, 1.68) 0.058 −0.5
Algometer score (kg/cm2)
TP group 45.42 ± 12.56 (37.92 to 52.92) 56.85 ± 15.28 (48.43 to 65.28) −11.43 (−18.38, −4.48) 0.004 0.8 F = 10.670.003 0.9
Control group 45.20 ± 14.68 (37.49 to 52.98) 42.79 ± 15.32 (34.05 to 51.53) 2.40 (−3.48, 8.29) 0.391 −0.1
Tender points
TP group 16.00 ± 3.38 (14.42 to 17.57) 14.13 ± 4.12 (12.42 to 15.84) 1.86 (0.56, 3.17) 0.008 −0.5 F = 7.900.009 0.8
Control group 16.50 ± 2.47 (14.86 to 18.13) 16.78 ± 1.84 (15.01 to 18.55) −0.28 (−1.25,0.68) 0.537 0.1
FIQ-R
TP group 59.44 ± 9.04 (52.14 to 66.74) 44.00 ± 15.21 (34.10 to 53.91) 15.43 (7.81, 23.05) 0.001 −1.2 F = 1.360.254 0.1
Control group 55.36 ± 16.46 (48.06 to 62.66) 46.90 ± 20.47 (36.99 to 56.81) 8.45 (−1.99, 18.90) 0.104 −0.4
PCS
TP group 24.8 ± 12.0 (18.27 to 29.47) 17.6 ± 12.4 (14.19 to 28.17) 7.00 (1.19, 12.80) 0.022 −0.6 F = 0.4150.525 0.4
Control group 24.10 ± 10.8 (15.72 to 28.40) 23.5 ± 14.0 (13.45 to 27.70) 1.07 (−4.54, 6.68) 0.687 0.0
Rumination
TP group 7.2 ± 3.8 (5.32 to 9.53) 5.1 ± 4.7 (2.45 to 7.69) 2.34 (−0.29, 5.01) 0.078 −0.5 F = 1.910.169 0.4
Control group 7.2 ± 3.6 (5.15 to 9.09) 6.9 ± 4.9 (4.42 to 9.32) 0.25 (−1.65, 2.15) 0.783 0.0
Helplessness
TP group 12.1 ± 6.3 (8.80 to 14.91) 8.9 ± 6.1 (5.19 to 12.65) 2.92 (0.46, 5.39) 0.023 −0.5 F = 0.4300.518 0.2
Control group 12.4 ± 5.2 (9.07 to 14.79) 10.2 ± 7.4 (6.69 to 13.67) 1.75 (−1.13, 4.63) 0.215 −0.3
Magnification
TP group 5.5 ± 2.9 (3.81 to 6.75) 3.6 ± 2.4 (2.97 to 5.07) 1.71 (0.38, 3.04) 0.015 −0.7 F = 2.050.163 0.1
Control group 4.4 ± 2.5 (3.12 to 5.87) 3.9 ± 3.0 (2.53 to 5.34) 0.56 (−0.55, 1.67) 0.300 −0.1
HADS
TP group 20.52 ± 6.83 (16.76 to 24.29) 11.70 ± 8.74 (7.21 to 16.19) 8.82 (3.33, 14.30) 0.004 −1.1 F=12.030.002 1.0
Control group 20.43 ± 8.37 (16.55 to 24.32) 21.25 ± 9.42 (16.62 to 25.88) −0.81 (−2.50, 0.87) 0.321 0.0
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Table 2. Cont.
Baseline
Mean ± SD (95% CI)
Postintervention











TP group 10.88 ± 3.38 (9.02 to 12.73) 6.29 ± 5.13 (3.86 to 8.72) 4.58 (1.69, 7.47) 0.004 −1.0 F = 10.250.003 0.9
Control group 10.81 ± 4.10 (8.90 to 12.72) 11.00 ± 4.66 (8.49 to 13.05) −0.18 (−1.27, 0.89) 0.718 0.0
HADS-D
TP group 9.64 ± 4.16 (7.49 to 11.81) 5.41 ± 4.13 (3.09 to 7.72) 4.23 (1.51, 6.95) 0.005 −1.0 F = 2.970.001 1.0
Control group 9.62 ± 4.58 (7.34 to 11.85) 10.31 ± 5.19 (7.92 to 12.69) −0.68 (−1.65, 0.27) 0.151 0.1
6MWT
TP group 403.57 ± 107.13 (327.90 to 480.14) 434.72 ± 73.78 (367.94 to 501.50) −30.70 (14.13, −61.50) 0.051 0.3 F = 1.540.225 −0.2
Control group 407.01 ± 137.09 (326.60 to 473.35) 411.72 ± 145.83 (347.37 to 476.07) −11.71 (−26.16, 2.73) 0.104 0.0
ACT
TP group 9.60 ± 4.31 (6.28 to 12.01) 11.38 ± 4.27 (8.57 to 14.19) −2.23 (−3.65, −0.81) 0.005 0.4 F = 3.980.056 −0.2
Control group 10.06 ± 5.56 (7.39 to 12.73) 10.33 ± 5.42 (7.72 to 12.94) −0.26 (−1.81, 1.27) 0.717 0.0
VAS: Visual Analogue Scale; FIQ-R: Fibromyalgia Impact Questionnaire; PCS: Pain Catastrophizing Scale; HADS: Hospital Anxiety and Depression Scale; HADS-A: Hospital Anxiety and Depression Scale–Anxiety
Subscale: HADS-D: Hospital Anxiety and Depression Scale–Depression Subscale; 6MWT: 6-min Walk Test; ACT: Arm Curl Test.
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4. Discussion
This randomized controlled clinical trial is the first study to investigate the effects of a
TP based on aerobic exercise in women with FM during the lockdown caused by COVID-19
pandemic. The results reported in this study showed that the TP group achieved statistically
significant improvements on pain intensity, mechanical pain sensitivity, and psychological
distress compared to a Control group.
Pain intensity, mechanical pain sensitivity, and psychological distress improved after
TP intervention. The change achieved on pain intensity was superior to the MCID (Minimal
Clinically Important Difference) described for patients with chronic pain [43]. The change
achieved on psychological distress was statistically significant and superior to the MCID
stated for patients with chronic disease [44]. However, the mean value at the end of the
treatment was higher than 8 points, considered the marked score for the diagnosis of
psychological distress [45]. These results are similar to previous studies showing that
aerobic exercise reduces pain intensity, mechanical pain sensitivity, and psychological
distress [16,46–49], however, in this clinical trial, we achieved improvements with a TP
without face-to-face sessions.
Regular exercise has shown to modify the levels of neurotransmitters, neuromodula-
tors, and the hypothalamic–pituitary function [50,51]. The changes in these elements are
related to improvements on pain, stress, anxiety, and depression among others in patients
with chronic pain [52,53]. In this way, the analgesic effect of exercise has shown to be related
to higher levels of endorphins [54]. Thus, the improvements on pain, mechanical pain
sensitivity, and psychological distress achieved in our study could be related to the increase
in neurotransmitters’ levels, especially, endorphins, release by the hypothalamus [50,51,54].
The TP group showed improvements on FM impact, pain catastrophizing, and upper
limb physical function. However, these changes were not enough to report statistically
significant differences between groups. The results of this study are in accordance with pre-
vious studies that found no differences comparing therapeutic exercise to usual care [25,55].
The intervention applied to the TP group could be an insufficient stimulus to improve
these variables. Concerning pain catastrophizing and FM impact, the aerobic exercise in
isolation could not be able to modify the beliefs and cognitions about pain. Other studies
reported that the addition of pain neurophysiology education to exercise therapy seems
to report better benefits on pain catastrophizing and FM impact than exercise therapy in
isolation [56–58].
Regarding the physical function, only the TP group showed a statistically significant
improvement in the upper limb physical function. No within- or between-groups differ-
ences were found for the rest of physical function variables. A recent systematic review
reported that aerobic exercise improves physical function [14], however, it is important to
mention that the current clinical trial was performed during the lockdown situation, so the
patients were not allowed to go out. The social and mobility restrictions during the study
period may explain the lack of improvements achieved in these variables.
From a clinical perspective, this study provides evidence suggesting that a TP in-
tervention based on aerobic exercise could be an effective strategy in FM patients, in the
exceptional situation caused by the COVID-19 pandemic. TP intervention could improve
FM symptoms in a safe way, without adverse events, and show high adherence level.
The individualized supervision performed by the physiotherapist allowed monitoring the
type of exercises, the intensity of the sessions, and the status of the patients, which seems
to be necessary to achieve a high adherence level and healthy habits in patients with FM.
The present study has potential limitations. First, men were not included in this study,
so results cannot be generalized to the entire population. Second, the intervention was
not compared with other experimental interventions, such a supervised exercise program.
Third, the reduced small sample size considered in the study made it difficult to achieve
between-group changes in some variables. Finally, there was a lack of follow-up analysis,
for this reason, the long-term effects of the study intervention were not reported.
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5. Conclusions
The results of this study showed that a TP based on aerobic exercise was effective for
reducing pain intensity, mechanical pain sensitivity, and psychological distress during the
lockdown caused by COVID-19 pandemic.
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